Lv2
121 积分 2021-04-02 加入
Perioperative Therapy for Resectable Non–Small-Cell Lung Cancer: Weighing Options for the Present and Future
13小时前
待确认
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: a multicenter single-arm phase 2 trial (NIke, LOGiK 2004)
14小时前
已完结
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance
14小时前
已完结
Immune Checkpoint Inhibitors as First-line Treatment for Brain Metastases in Stage IV NSCLC Patients without Driver Mutations
14小时前
已完结
Patterns of brain metastases response to immunotherapy with pembrolizumab
14小时前
已完结
Nivolumab plus ipilimumab with chemotherapy for non–small cell lung cancer with untreated brain metastases: a multicenter single-arm phase 2 trial (NIke, LOGiK 2004)
14小时前
已关闭
Pembrolizumab for advanced non-small cell lung cancer (NSCLC): Impact of autoimmune comorbidity and outcomes following treatment completion
3天前
已完结
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
18天前
已完结
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
26天前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
26天前
已完结
皖公网安备34019202002308
